ICU Medical Q2 2026 Earnings: Organic Growth Supports Higher Guidance

ICU Medical (Nasdaq: ICUI) reported Q2 2026 revenue of $551.7 million, up 1% from $548.9 million a year earlier, while GAAP diluted EPS fell to $0.76 from $1.43. Organic revenue increased 6% after excluding the IV Solutions divestiture and foreign-currency effects, led by Infusion Systems, while adjusted diluted EPS rose to $2.37. Quarterly cash generation improved, and the company raised its fiscal 2026 earnings guidance.

Core Earnings Data

Reported revenue growth was limited by the May 2025 divestiture of the IV Solutions business. On a comparable organic basis, the remaining portfolio expanded faster, with Infusion Systems and Consumables offsetting continued weakness in Vital Care.

Profit measures diverged because of transaction-related items. GAAP operating income increased substantially, but GAAP net income declined because the prior-year quarter included a $41.8 million gain on the sale of a business; adjusted EPS and adjusted EBITDA both increased.

Adjusted results exclude items including stock compensation, amortization, restructuring and integration costs, quality remediation expenses, tariff refunds and other special items.

Business and Product-Line Performance

Infusion Systems was the principal growth driver, increasing 13% on a reported basis and 12% organically. Consumables also expanded, while Vital Care’s reported decline largely reflected the IV Solutions divestiture; even after adjusting for the transaction and currency, however, Vital Care organic revenue decreased 4%.

CEO Vivek Jain said Infusion Systems performed ahead of the company’s expectations, while the remainder of the business was generally in line with expectations. The product-line data support that distinction: Infusion Systems generated the fastest growth, while Vital Care remained the main drag on the underlying portfolio.

Tariff Refunds Lifted GAAP Margins, While a Prior-Year Gain Weighed on EPS Comparability

A $18.9 million tariff refund was recorded in Q2 2026 and increased GAAP gross profit. That helped raise the reported gross margin to 43% from 38%, but the adjusted gross margin—which excludes the refund and other specified items—rose more moderately to 41% from 40%. Adjusted operating margin still improved to 17% from 14%, indicating that the increase was not entirely attributable to the refund.

The opposite comparison affected net income. Q2 2025 included a $41.8 million gain from the sale of a business, while no comparable gain was recorded in Q2 2026. Consequently, GAAP net income and diluted EPS declined even as operating income, adjusted EPS and adjusted EBITDA increased. Net interest expense also improved to $15.7 million from $20.5 million, providing an additional benefit below the operating line.

Profitability, Cash Flow and Balance Sheet

The quarterly cash-flow improvement carried through to the first-half results. Operating cash flow for the six months ended June 30 increased to $119.1 million from $62.5 million, while free cash flow rose to $89.3 million from $28.3 million. A $4.6 million cash inflow from inventory during the first half, compared with a $29.2 million inventory outflow a year earlier, contributed to the change.

Cash and equivalents nevertheless decreased by $9.7 million from the end of 2025 to $298.3 million. Financing activities used $94.4 million during the first half, including $54.7 million of long-term debt repayments and $38.9 million of tax-withholding payments related to equity awards. Capital expenditures were $29.8 million.

Total reported long-term debt, including the current portion, was $1.23 billion at June 30. ICU Medical calculated non-GAAP net debt of $941.5 million and a net leverage ratio of 2.28 times trailing-12-month adjusted EBITDA. Inventory declined to $607.4 million from $615.9 million at the end of 2025.

Fiscal 2026 Guidance

ICU Medical raised both ends of all four disclosed fiscal 2026 guidance ranges. The increases extended beyond GAAP measures: adjusted EBITDA and adjusted diluted EPS guidance also moved higher, indicating an improved outlook for the company’s adjusted operating performance.

The annual reconciliation excludes $19 million of tariff refunds from adjusted results, along with stock compensation, amortization, restructuring, quality and regulatory remediation, and specified tax items.

Recent Insider Transactions

The provided six-month insider summary classifies 395,121 shares across 18 transactions as purchases and 6,994 shares across three transactions as sales, resulting in 388,127 net shares purchased. Total insider holdings were listed at approximately 479,380 shares, but the summary does not establish whether all classified purchases were open-market transactions.

The following table includes the latest entries with a disclosed transaction action and value; records lacking transaction details are omitted.

These transactions are presented as reported and do not, on their own, establish insiders’ views about the company’s outlook.

Risks Investors Should Monitor

• Vital Care remains under pressure. Its reported revenue declined 32%, and organic revenue fell 4% even after excluding the divested business and currency effects. Continued weakness could offset growth in Infusion Systems and Consumables.
• Part of the GAAP margin improvement came from a special item. The $18.9 million tariff refund materially benefited Q2 gross profit, while the adjusted gross-margin increase was only one percentage point. Similar refunds may not recur in future periods.
• Restructuring and quality-related expenses remain meaningful. The quarter included $21.3 million of restructuring, strategic transaction and integration costs and $5.9 million of quality-system and product-remediation expenses, creating a substantial gap between GAAP and adjusted earnings.
• Debt and interest costs remain significant. Net debt was $941.5 million, the net leverage ratio was 2.28 times, and quarterly net interest expense was $15.7 million. Debt service therefore continues to absorb a portion of operating cash flow despite recent repayments.

Summary

ICU Medical’s Q2 2026 results showed stronger growth in the continuing portfolio than the 1% reported revenue increase suggests, with Infusion Systems leading a 6% organic gain. Adjusted earnings and cash flow improved, while GAAP comparisons were distorted by a current-quarter tariff refund and a prior-year divestiture gain. The raised fiscal 2026 guidance is the main forward-looking change, with Vital Care performance, underlying margins, remediation costs and leverage remaining the principal areas to monitor.